AU1676992A - Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers - Google Patents
Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymersInfo
- Publication number
- AU1676992A AU1676992A AU16769/92A AU1676992A AU1676992A AU 1676992 A AU1676992 A AU 1676992A AU 16769/92 A AU16769/92 A AU 16769/92A AU 1676992 A AU1676992 A AU 1676992A AU 1676992 A AU1676992 A AU 1676992A
- Authority
- AU
- Australia
- Prior art keywords
- macromolecular conjugate
- group
- polymer
- glycopolypeptide
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
HYDRAZINE CONTAINING CONJUGATES OF POLYPEPTIDES AND GLYCOPOLYPEPTIDES WITH POLYMERS Technical Field
The present invention relates to biologicall active macromolecular conjugates, in particular, t conjugates of biologically active polypeptides an glycopolypeptides with water-soluble polymers. Background Art
The conjugation of polypeptides wit water-soluble polymers such as polyethylene glycol (PEG) is well known. The coupling of peptides an polypeptides to PEG and similar water-soluble polymers is disclosed by U.S. Patent No. 4,179,337 to Davis et al. Davis et al. discloses that physiologically active polypeptides modified with PEG exhibit dramatically reduced immunogenicity and antigenicity. Also, the PEG-protein conjugates, when injected into a living organism, have been shown to remain in the bloodstream considerably longer than the corresponding native proteins. Accordingly, a number of PEG-conjugated therapeutic proteins were developed exhibiting reduced immunogenicity and antigenicity and longer clearance times, while retaining a substantial portion of the protein's physiological activity. Significant PEG-conjugated therapeutic proteins include tissue plasminogen activator, insulin, interleukin 2 and hemoglobin. Furthermore, Dreborg et al., Crit. Rev. Therap. Drug Carrier Syst.. 6 , 315-65 (1990) disclose that covalent modification of potent allergen proteins with PEG often can be effective in reducing their allergenicity. Sehon, et al., Pharmacol. Toxicol. Proteins. 65, 205-19 (1987) disclose that such PEG-conjugated allergen proteins having reduced allergenicity can then be utilized as tolerance inducers.
In most instances, as exemplified by U.S. Patent No. 4,179,337, covalent attachment of the polymer
is effected by reacting PEG-succinimide derivatives with amino groups on the exterior of protein molecules. However, the amino groups of many proteins are moieties responsible for polypeptide activity that can be readily inactivated as a result of such modification. The conjugation of such proteins is not desirable, because it results in the reduction of physiological activity. Other proteins may have only a small number of available amino groups, and consequently very few polymer anchoring sites. As a result, many proteins of interest cannot be conjugated with PEG in this manner.
The known alternatives to covalent attachment of polymers to other functional groups on the exterior of proteins have serious limitations. U.S. Patent No. 4,179,337 discloses, for example, that PEG-maleimide derivatives can be used to covalently attach polymers to protein sulfhydryl groups. However, this is of limited versatility because very few proteins have free sulfhydryl groups that are not required for biological or enzymatic activity and would thus be available for chemical modification.
U.S. Patent No. 4,179,337 discloses the reaction of an amino-PEG derivative with l-ethyl-3-(3-dimethylamino-propyl) carbodiimide(EDC)- activated carboxylic acid groups of trypsin and other proteins. The selectivity of this reaction is rather poor because the reactivity of amino-PEG is similar to that of the lysyl residues of proteins, with both the amino-PEG and protein amino groups competing to react with the activated carboxylic acid groups. This results in intermolecular as well as intramolecular crosslinking and a loss of protein activity.
In a similar reaction disclosed by Pollack et al., JACS, 98., 289 (1976), p-aminobenzyl ethers of PEG are coupled to carboxylic acid groups of
D-glucose-6-phosphate dehydrogenase by treatment with
EDC.
A polymer derivative that protein amino group would not compete with for activated carboxylic aci groups of proteins would be highly desirable. Thi would eliminate inter olecular and intramolecula crosslinking and improve the enzymatic activity o polymer conjugates.
U.S. Patent No. 4,847,325 to Shadle et al. suggests that glycosilated Colony Stimulating Factor- (CSF-l) could be covalently attached to PEG by reactin PEG-amine, PEG-hydrazine or PEG-hydrazide with CSF- that had been oxidized with periodate to convert vicina diols in the sugars to aldehydes. However, thi disclosure is silent regarding the details o preparation of such conjugates and their reactivity. The degree of polymer conjugation with amin groups is ordinarily determined by assaying th conjugate with trinitrobenzene sulfonic acid (TNBS) t determine the number of free amino groups. For polymer conjugated at protein amino groups, the differenc between the number of free amino groups in the modifie protein and the number of free amino groups in th native protein represents the degree of conjugation o the protein.
The results from TNBS assays are meaningless when determining the degree of conjugation of proteins when the polymer is covalently attached to alternative functional groups. In such instances, the number of free amino groups will not vary between conjugated and non-conjugated protein species. The conjugated protein can also be digested in small fragments with an enzyme and separated by column chromatography followed by preparation of a peptide map for comparison to a map of the unmodified protein, with the fragments having altered elution times indicative of the location of polymer attachments. However, this procedure consumes large quantities of product and is not suitable for use with polypeptides of limited availability. Radioactive labeling represents another
alternative, but this alternative is not suitable for materials being prepared for therapeutic end uses for which the determination of degree of conjugation is most critical. Yamasaki et al., Agric. Biol. Chem. , 52(8) f
2125-7 (1988) disclose the preparation of PEG-succinimide derivatives with norleuσine and lysine residues between the polymer and the succini ido moiety, which residues permit the measurement of the amount of PEG covalently attached to the amino groups of proteins by amino acid analysis for the presence of norleucine or lysine. Sartore et al., Proced. Intern. Sym. Control. Rel. Bioact. Mater., 17, 208-9 (1990) also disclose the use of a norleucine spacer in PEG-succinimide derivatives covalently bonded to protein amino groups, noting that the use of such an unnatural amino acid helps in the characterization of the adduct because a single amino acid analysis would give both protein concentration and number of polymer chains bound to the amino groups. In other words, in the purified conjugate, each single norleucine residue acid represents a polymer chain bound to an exterior amino grou .
There remains a need for methods to covalently attach polymers to non-amino moieties of polypeptides and glycopolypeptides without a loss of activity from intermolecular crosslinking, as well as for methods of assaying the degree of conjugation of the polymer to the polypeptide at functional groups other than amino groups.
Summary of the Invention
It has now been discovered that water-soluble polymers can be conjugated with biologically active polypeptides and glycopolypeptides utilizing acyl hydrazine derivatives of the water-soluble polymers. The acyl hydrazine derivatives of the water-soluble polymers covalently link to either the oxidized carbohydrate residues of the glycopolypeptides or the
reactive carbonyl or activated carboxylic acid groups o peptide moieties of polypeptides or glycopolypeptides This invention extends the realm of water-solubl polymer-peptide conjugation to those polypeptide an glycopolypeptide materials that could not have bee modified heretofore by conventional methods Furthermore, under neutral or mildly acidic condition o conjugation reactions, due to their low pKa (about 3 acyl hydrazine containing polymers of this inventio possess higher reactivity than the amino groups o polypeptides (pKa about 10.5), therefore minimizing an in most cases eliminating the competing reactions o these amino groups, thus preventing polypeptid crosslinking and preserving the biological activity o the conjugates.
In accordance with the present invention, biologically active macromolecular conjugate is provide of a biologically active polypeptide or glycopolypeptid and one or more water-soluble polymer molecule covalently bonded thereto at a reactive carbonyl o carboxylic acid group of a peptide moiety on th polypeptide or glycopolypeptide by a linkage containin a hydrazide or hydrazone functional group. The linkag is formed by reacting an acyl hydrazine derivative o the water-soluble polymer with a polypeptide o glycopolypeptide having an activated carboxylic aci group or a reactive carbonyl group generated thereon.
The present invention also provides biologically active macromolecular conjugate of biologically active glycopolypeptide and one or mor water-soluble polymer molecules covalently bonde thereto at an oxidized carbohydrate moiety of th glycopolypeptide by a linkage containing a hydrazide o hydrazone functional group bound to the polymer via short peptide sequence. The oxidation of th carbohydrate moiety produces reactive aldehydes. Th hydrazone linkage is formed by reacting an acy hydrazine derivative of the water-soluble polyme
containing the peptide sequence with these aldehyde groups. The hydrazone can be further stabilized by reduction to a very stable alkyl hydrazine derivative.
The peptide sequence influences the lability of the linkage to proteolytic enzymes and also allows convenient characterization of the polymer conjugates by amino acid analysis of their hydrolysates. By using state-of-the-art techniques of amino acid analysis, the quantity of peptide sequences, and consequently the degree of conjugation, can be determined for picomolar concentrations of the conjugate.
Therefore, it is also in accordance with the present invention that the peptide sequences also be utilized with the polypeptide conjugates of the present invention to bind the linkages containing a hydrazide or hydrazone functional group to the water-soluble polymer. Brief Description of the Drawings
FIG. 1 is a GF-HPLC chromatogram comparison of mPEG-beta-alanine-bovine serum albumin conjugate to native bovine serum albumin.
FIG. 2 is a GF-HPLC chro atogram comparison of mPEG-beta-alanine-ovalbumin conjugate to native ovalbumin.
FIG. 3 is a GF-HPLC chromatogram comparison of PEG-beta-alanine-IgG, conjugated via oxidized carbohydrate moieties, to native IgG.
FIG. 4 is a GF-HPLC chromatogram comparison of PEG-beta-alanine-rhG-CSF, conjugated via carboxylic acid groups of rhG-CSF, to native rhG-CSF. Best Mode of Carrying Out the Invention
The macromolecules of the present invention are biologically active polypeptides or glycopolypeptides having one or more water-soluble polymer molecules covalently bonded thereto. The term "biologically active" is used consistently with the meaning commonly understood to those of ordinary skill in the polypeptide and glycopolypeptide art, which meaning is not limited to physiologically or
pharmacologically activities of the polypeptides or glycopolypeptides in the therapeutic sense. For example, many physiologically active polypeptides such as enzymes, the water-soluble polymer conjugates of which have therapeutic applications, are also able to catalyze reactions in organic solvents. Likewise, while therapeutic uses exist for water-soluble polymer conjugates of proteins such as concanavalin A, immunoglobulins, and the like, the polymer conjugates of these proteins are also useful as laboratory diagnostic tools.
Enzymes of interest, for both biological applications in general and therapeutic applications in particular include the oxidoreductases, transferases, hydrolases, lyases, isomerases and ligases disclosed by U.S. Patent No. 4,179,337, the disclosure of which is hereby incorporated herein by reference thereto. Without being limited to particular enzymes, examples of specific enzymes of interest include asparaginase, arginase, adenosine deaminase, superoxide dismutase, catalase, chymotrypsin, lipase, uricase and bilirubin oxidase. Carbohydrate-specific enzymes are also of interest—for example, glucose oxidase, glucosidase, galactosidase, glucocerebrosidase, glucuronidase, etc. Examples of other proteins of general biological or therapeutic interest include, but are not limited to, Factor VIII and polypeptide hormones such as insulin, ACTH, glucagon, somatostatin, somatotropins, thymosin, parathyroid hormone, pigmentary hormones, somatomedins, erythropoietin, luteinizing hormone, hypothamic releasing factors, antidiuretic hormones and prolactin.
Examples of glycopolypeptides of interest include, but are not limited to, immunoglobulins, chorionic gonadotrophin, follicle-stimulating hormone, thyroid-stimulating hormone, ovalbumin, bovine serum albumin (BSA) , lectins, tissue plasminogen activator, numerous enzymes and glycosilated interleukins,
interferons and colony stimulating factors. Immunoglobulins of interest include IgG, IgE, IgM, IgA, IgD and fragments thereof.
Many of the above glycopolypeptides such as the interleukins, interferons and colony stimulating factors also exist in non-glycosilated form, usually the result of preparation by recombinant protein techniques. The structure of such versions may not contain carbohydrate moieties. However, the non-glycosilated versions are still capable of conjugation at reactive carbonyl or carboxylic acid groups of the peptide moieties.
Examples of allergen proteins and glycoproteins having reduced allerginicity when conjugated with water-soluble polymers and consequently suitable for use as tolerance inducers include those allergens disclosed by Dreborg et al., Crit. Rev. Therap. Drug Carrier Syst.. discussed above, the teachings of which are hereby incorporated herein by reference thereto. Among the allergens disclosed by this article are Ragweed Antigen E, honey bee venom, mite allergen, and the like.
The water-soluble polymers suitable for attachment to the polypeptides and glycopolypeptide include polyalkylene oxides, polyoxyethylenated polyols, polyacrylamides, polyvinyl pyrrolidone, polyvinyl alcohol, dextran, and other carbohydrate-based polymers.
To be suitable for use in the present invention, the polymer must be soluble in water at room temperature. Polyalkylene oxide homopolymers meeting this requirement are polyethylene glycol (PEG) and copolymers thereof.
Block copolymers of PEG with polypropylene glycol or polypropylene oxide are also suitable for use with the present invention, provided that the degree of block copolymerization is not so great as to render the polymer insoluble in water at room temperature.
Examples of polyoxyethylenated polyols include
polyoxyethylenated glycerols, polyoxyethylenate sorbitols, polyoxyethylenated glucoses, and the like.
The molecular weight of the polymer is no critical, and will depend mainly upon the end use of particular polymer conjugate. Those of ordinary skil in the art are capable of determining molecular weigh ranges suitable for their end use applications. I general, the useful range of molecular weight is number average molecular weight between about 600 an about 100,000 daltons, and preferably betwee about 2,000 and about 20,000 daltons.
One or more polymer units can be attache covalently to the polypeptide or glycopolypeptide b reacting an acyl hydrazine derivative of the polyme with a polypeptide or glycopolypeptide having a reactiv carbonyl group or an activated peptide carboxylic aci group. For purposes of the present invention, th reactive carbonyl group is defined as being either ketone or aldehyde group, excluding othe carboxyl-containing groups such as amides. Aldehyd groups are preferred, because they are more reactiv than ketones.
The carbonyl group can be generated either o a peptide or a saccharide unit. For example, Dixon, J. Protein Chem.. 3., 99 (1984) has reviewed some of the methods to generate reactive carbonyl groups on the N-terminus of a polypeptide molecule. Carbonyl groups can be generated on peptides, for example, by reacting a polypeptide or glycopolypeptide with a suitable heterobifunctional reagent such as a reactive ester of formyl benzoic acid, disclosed by King et al.. Biochemistry, 25. 5774 (1986) , the teachings of which are hereby incorporated herein by reference thereto. Carbonyl groups can be generated on saccharide units of glycopolypeptides, for example, by oxidizing vicinal diols of carbohydrate moieties of glycopolypeptides with excess periodate or enzymatically e.g. by use of galactose oxidase.
The polymer acyl hydrazine reacts with the reactive carbonyl group on the polypeptide or glycopolypeptide to form a hydrazone linkage between the polymer and the polypeptide or glycopolypeptide. The hydrazone can be reduced to a more stable alkyl hydrazide by using for example NaBH4 or NaCNBH3.
The activated peptide carboxylic acid group can be derived either from a C-terminus carboxylic acid group or a carboxylic acid group of aspartic or glutamic acid residues. The polymer acyl hydrazine reacts with the activated peptide carboxylic acid group to form a diacylhydrazine linkage between the polymer and the polypeptide or glycopolypeptide.
Activated carboxylic acid groups are carboxylic acid groups substituted with a suitable leaving group capable of being displaced by the polymer acyl hydrazine. Examples of suitable leaving groups are disclosed by Bodanszky, Principles of Peptide Synthesis (Springer-Verlag, New York, 1984) , the disclosure of which is hereby incorporated herein by reference thereto. Such leaving groups, which are well-known in the art of peptide chemistry, include, but are not limited to, imidazolyl, triazolyl, N-hydroxysuccin- imidyl, N-hydroxynorbornenedicarboximidyl and phenolic leaving groups, and are substituted onto the peptide carboxylic acid group by reacting the polypeptide or glycopolypeptide in the presence of an activating reagent with the corresponding imidazole, triazole , N-hydroxysuccinimide, N-hydroxynorbornene dicarboximide and phenolic compounds.
Suitable activating reagents are also well-known and disclosed by the above-cited Bodanszky, Principles of Peptide Synthesis, the disclosure of which is hereby incorporated herein by reference thereto. Examples of such activating reagents include, but are not limited to, water-soluble carbodiimides such as ethyl dimethyla ino-propyl carbodiimide (EDC) and 3-[2-morpholinyl-(4)-ethyl] carbodiimide, p-toluene
sulfonate, 5-substituted isoxazolium salts, such a Woodward's Reagent K, and the like.
The acyl hydrazine polymer derivatives of th present invention will have the general structure (I) :
_
X-R-Z-C-NH-NH2 (I) wherein R is one of the above-disclosed water-solubl polymers, Z is 0, NH, S or a lower alkyl grou containing up to ten carbon atoms, and X is a termina group on the polymer. X can be a hydroxyl group, i which case the polymer has two labile groups per polyme moiety capable of reacting to form a derivative that can be covalently linked with a polypeptide or glycopolypeptide. X can therefore also be a group into which the terminal hydroxyl group may be converted, including the reactive derivatives of the prior art disclosed in U.S. Patent Nos. 4,179,337 and 4,847,325, the disclosures of which are hereby incorporated herein by reference thereto, as well as the acyl hydrazine derivatives of the present invention. Such heterobi¬ functional polymers can be prepared by methods known to those skilled in the art, including the methods disclosed by the present specification with reference to the preparation of acyl hydrazine derivatives, as well as the methods disclosed by Zalipsky and Barany, Polym. Prepr.. 27(1.. 1 (1986) and Zalipsky and Barany, J. Bioact. Compat. Polym.. 5 , 227 (1990), the disclosures of which are hereby incorporated herein by reference thereto. Where X is a functional group useful for covalently linking the polymer with a second polypeptide or glycopolypeptide, X can be a solid support or a small molecule such as a drug, or an acyl hydrazide derivative of the formula (II) :
-Z-C-NH-NH- (II)
When Z is the same as disclosed above for acyl hydrazine derivatives, the polymer will then be a symmetrical, homobifunctional polymer derivative.
Such double polymer substitution can result in either intra- or intermolecular crosslinking of the polypeptide and glycopolypeptide moieties, which, in some cases, can be useful. Such crosslinking can be controlled by the amount of polymer used and the concentration of reacting species, which methods are well-known to those of ordinary skill in the art.
Crosslinking of the polypeptide or glycopolypeptide moieties can also be prevented by using a pre-blocked polymer having only one labile hydroxyl group per polymer moiety. With such polymers, X would represent a blocking group such as an alkoxy group of one to four carbon atoms. The preferred blocking group is a methoxy group.
In any event, the selectivity of the acyl hydrazines for the reactive carbonyl or activated carboxylic acid groups over the peptide amino group prevents intermolecular crosslinking between peptide amino groups and the reactive carbonyl groups and activated carboxylic acid groups, limiting occurrences of such crosslinking to instances when bifunctional polymer derivatives are employed.
X can also represent an antibody or solid support covalently coupled to the polymer by methods known to those skilled in the art. Examples of solid supports covalently coupled to water-soluble polymers and methods of coupling water-soluble polymers to solid supports are disclosed in Published European Patent Application No. 295,073, the disclosure of which is hereby incorporated herein by reference thereto.
The acyl hydrazine derivative is prepared by reacting, for example, the terminal -OH group of methoxylated PEG (mPEG-OH) with phosgene to form mPEG-chloroformate as described in U.S. Patent Appln.
Ser. No. 340,928 by Zalipsky, filed April 19, 1989, the
disclosure of which is hereby incorporated herein b reference thereto. The reaction is carried out i organic solvents in which the reactants are soluble, such as methylene chloride, and will run to completio overnight at room temperature. The solvents and exces phosgene are removed and the residue of polymeri chloroformate is then reacted with an excess o hydrazine.
The preparation of acyl hydrazine polyme derivatives is described with reference to mPEG fo purposes of illustration, not limitation. Simila products would be obtained with any of the polymer suitable for use with the present invention, and it wil be clear to those of ordinary skill in the art how thi preparation can be adapted to the other suitabl polymers.
A more preferred form of the present inventio uses polymer hydrazides of the general formula (III) :
X-R-Z .--CC--AAAA--NNHH--1NH2 (III) wherein R represents the water-soluble polymers, Z represents the groups described above with respect t Formula I, X represents the polymer terminal group described above and AA represents an amino acid or a peptide sequence. AA can be a peptide sequence of any of the common amino acids, or at least one amino acid residue. In the case of AA being one amino acid residue, it is preferable that it is a residue that does not appear naturally in proteins. Examples of such unusual residues include, but are not limited to, alpha- or gamma- amino butyric acid, norleucine, homoserine, beta-alanine, epsilon-caproic acid, and the like.
When Z is oxygen, the linkage is a urethane linkage, which is very stable at ambient temperature in a variety of buffers, even at extreme pH's, but is readily split under conditions normally used for protein hydrolysis, thus allowing determination of amino acid components of AA by amino acid analysis.
The peptide sequence can serve two roles. First, it can provide for convenient characterization of the modified protein by quatitation of the sequence by amino acid analysis. In this instance, the peptide sequence preferably is as short as possible and preferably contains unusual amino acid residues. For characterization of the modified protein, the peptide sequence most preferably contains but one amino acid.
In addition, AA can also contain a labeled amino acid residue (chromophore, fluorophore, or radioisotope containing) , or an amino acid that could be easily labeled (e.g. tyrosine can be iodinated) . The presence of such labels would facilitate the experimental evaluation of . the resulting polymer- polypeptide conjugates.
Second, the peptide sequence can optimize the lability of the covalent linkage between the water-soluble polymer and the polypeptide to proteolytic enzymes. In this second instance, the peptide sequence is preferably as long as possible and preferably contains natural amino acid residues. By controlling enzymatic lability in this manner, the polymer conjugates can be used to deliver physiologically active polypeptides or glycopolypeptides to specific sites, such as cancer cells having elevated concentrations of certain proteolytic enzymes to which the peptide sequence is labile.
The length and sequence of the peptide in this second instance can be fine-tuned depending on the system of use and specificity of the target enzyme. Usually, three to seven amino acid residues would be required. Using modern techniques of peptide chemistry such short peptide sequences can be readily assembled.
In symmetrical, homobifunctional polymer derivatives, X can also contain a second peptide sequence residue. For example, when X is an acyl hydrazine derivative, X would have the general formula
(IV):
O II -Z-C-AA-NH-NH2 (IV) wherein Z and AA are as described above.
The acyl hydrazine polymer derivativ containing a peptide sequence can be synthesized b first preparing the polymeric chloroformate as describe above. The polymeric chloroformate is then reacted wit the peptide or an amino acid derivative in a solvent i which the polymeric chloroformate is soluble, such a ethylene chloride. The peptide or amino acid i preferably in the form of the ester of the C-terminu acid group, more preferably methyl or ethyl esters.
This reaction is also operative under mil conditions and typically runs to completion at roo temperature and* the resulting product can be readil converted to a hydrazide by hydrazinolysis. The acy hydrazine polymer derivative containing a peptid sequence is then recovered and purified by conventiona methods, such as repeated precipitation of the polymer product.
Alternatively, the acyl hydrazine polyme derivative containing a peptide sequence or an amin acid can be prepared by reacting the peptide sequenc with a succinimidyl carbonate active ester of th polymer, as disclosed by the above-mentioned Zalipsky, U.S. Patent Appln. No. 340,928 or by directly reactin isocyanate derivatives of an amino acid with th terminal hydroxyl group of the polymer as disclosed b Zalipsky et al.. Int. J Peptide Protein Res.. 30. 740 (1987) , the disclosures of both of which are hereby incorporated herein by reference thereto. Again, both reactions are essentially conventional and operative under mild conditions, running to completion at room temperature in organic solvents in which the polymer is solvent, such as methylene chloride. The reaction of isocyanate derivatives of amino acid esters with terminal hydroxyl groups of polymers is disclosed in the above-cited Zalipsky and Barany, Polv . Prepr.. as well
as in Zalipsky et al., Int. J. Peptide Protein Res.. the teachings of both of which are hereby incorporated herein by reference thereto. The succinimidyl carbonate derivative of the polymer is formed by the known method of reacting the above-disclosed polymeric chloroformate with N-hydroxysuccinimide, as disclosed by the above-cited Zalipsky, U.S. Patent Appln. No. 340,928, the disclosure of which is hereby incorporated herein by reference thereto. Either of the above polymer-polypeptide derivatives can be readily converted to a hydrazide by the hydrazinolysis method disclosed above to yield an acyl hydrazine. The preparation of peptide sequences is essentially conventional and disclosed by the above-cited Bodanszky, Principles of Peptide Synthesis, the disclosure of which is hereby incorporated herein by reference thereto.
The reaction of polymer acyl hydrazine derivatives with carbonyl-containing polypeptides and glycopolypeptides to form a hydrazone linkage is illustrated by the reaction sequence of Scheme 1 in which R represents the above-described water-soluble polymers, Z is as described above with respect to Formulae I-IV and either or both of R^ anc^ R2 are independently selected from oxidized carbohydrate moieties of glycopolypeptides and peptide units of polypeptides and glycopolypeptides on which reactive carbonyl groups have been generated:
Scheme 1
Hydrazide
The hydrazone can be reduced to the more stable alkyl hydrazide by reacting the hydrazone with, for example, NaBH4 or NaCNBH3.
The reaction of polymer acyl hydrazine derivatives containing peptide sequences, with carbonyl-containing polypeptides and glycopolypeptides is shown in Scheme 1A, in which R, Rlf R2 and Z are the same as described above with respect to Scheme 1 and AA represents the above-described peptide sequence:
Scheme 1A
Hydrazide
The reaction of polymer acyl hydrazine derivatives with activated peptide carboxylic acid groups of polypeptides and glycopolypeptides to form
diacylhydrazides is illustrated by the reaction sequence of Scheme 2: Scheme 2
0 0 1) || activation |
R3-C-OH e.g., EDC R3-C-R4
2) R3- ?C-R4 + R-Z-C _-NH-NH2 R-Z-C _-NH-NH- ?C-R3 Diacylhydrazide
R again represents the above-described water-soluble polymers, and Z is the same as described above for Formulae I-IV. R3 represents a polypeptide containing aspartic acid, glutamic acid or a C-terminus carboxylic acid residues. R4 represents one of the above-described leaving groups substituted on the peptide carboxylic acid when the carboxylic acid group is activated as described above.
The reaction of polymer acyl hydrazine derivatives containing peptide sequences, with activated peptide carboxylic acid groups of polypeptides and glycopolypeptides is shown in Scheme 2A, in which R, R3,
R4 and Z are the same as described above with respect to
Scheme 2, and AA represents the above-described peptide sequence:
Scheme 2A
O 0
1) . activation li
R3-C-0H e.g., EDC R3~C-R4
2) R3-C-R4 + R-Z- - ϊCC--AAAA--NNHH--NNHH2. 4■> RR --ZZ--CC--AAAA--NNHH--NNHH--CC--IR3
Diac lhydrazide Generally, the conjugation of a polypeptide or glycopolypeptide with a water-soluble polymer first involves either oxidizing carbohydrate moieties of the glycopolypeptide or activating carboxylic acid groups of peptide moieties of the polypeptides or glycopolypeptides. The carbohydrate moieties can be
oxidized by reacting the glycopolypeptide in aqueous solution with sodium periodate or enzymatically usin galactose oxidase or combination of neuraminidase an galactose oxidase as disclosed by Solomon et al., J. Chromatographv. 510. 321-9 (1990) . The reaction runs rapidly to completion at room temperature. The reaction medium is preferably buffered, depending upon the requirements of the polypeptide or glycopolypeptide. The oxidized glycopolypeptide is then recovered and separated from the excess periodate by column chro atography.
Carboxylic acid groups of peptide moieties can be activated by reacting the polypeptide or glycopolypeptide with an activating reagent such as a water-soluble carbodimide such as EDC. The reactants are contacted in an aqueous reaction medium at a pH between about 3.0 and 8.0, and preferably about 5.0, which medium may be buffered to maintain the pH. This reaction is taking place under mild conditions (typically 4 to 37 C) that are tolerated well by most proteins.
Polypeptides or glycopolypeptides having peptide units on which reactive carbonyl groups have been generated may be directly reacted with the acyl hydrazine polymer derivatives in an aqueous reaction medium. This reaction medium may also be buffered, depending upon the pH requirements of the polypeptide or glycopolypeptide and the optimum pH for the reaction, which pH is generally between about 5.0 and about 7.0 and preferably about 6.0.
In all instances, the optimum reaction media pH for the stability of particular polypeptides or glycopolypeptides and for reaction efficiency, and the buffer in which this can be achieved, is readily determined within the above ranges by those of ordinary skill in the art without undue experimentation. For purposes of this application, the operativeness of the within reactions under mild conditions is defined as
meaning that the preferred temperature range is between about 4 and about 37 XC. Those of ordinary skill in the art will understand that the reactions will run somewhat faster to completion at higher temperatures, with the proviso that the temperature of the reaction medium cannot exceed the temperature at which the polypeptides or glycopolypeptides begin to denature. Furthermore, those of ordinary skill in the art will understand that certain polypeptides and glycopolypeptides will require reaction with the polymer acyl hydrazine derivatives at reduced temperatures to minimize loss of activity and/or prevent denaturing. The reduced temperature required by particular polypeptides and glycopolypeptides is preferably no lower than 4ΛC and in no event should this temperature be lower than 0 C. The reaction will still take place, although longer reaction times may be necessary.
Usually, the polypeptide or glycopolypeptide is reacted in aqueous solution with a quantity of the acyl hydrazine polymer derivative in excess of the desired degree of conjugation. This reaction also proceeds under mild conditions, typically at 4 to 37XC.
The reaction medium may be optionally buffered, depending upon the requirements of the polypeptide or the glycopolypeptide, and the optimum pH at which the reaction takes place. Following the reaction, the conjugated product is recovered and purified by diafiltration, column chromatography or the like. When the acyl hydrazine polymer derivative includes an amino acid or a peptide sequence, the degree of polymer conjugation of the polypeptide or glycopolypeptide can then be determined by amino acid analysis.
In view of the foregoing, it can be readily appreciated that the acyl hydrazine polymer derivatives of the present invention possess the optimum balance of reactivity and selectivity so that polymer conjugates can be formed with non-amino functional groups of polypeptides and glycopolypeptides with virtually no
competition between the acyl hydrazines and the peptid amino groups for the non-amino functional groups. Thus, crosslinking is prevented and the activity of th polypeptide or glycopolypeptide is preserved. The following non-limiting examples set fort hereinbelow illustrates certain aspects of th invention. All parts and percentages are by weigh unless otherwise noted, and all temperatures are i degrees Celsius. EXPERIMENTAL
MATERIALS:
Methoxy-PEG (mPEG) is available fro Union Carbide. The solvents used, as well as beta-alanine ethyl ester HCL, hydrazine, P2°5' EDC, N-hydroxy-5-norbornene-2,3-dicarboximide (HONb) , NaCNBH3 and NaI04 are available from Aldrich Chemicals of Milwaukee, Wisconsin. Chymotrypsin was obtained from Worthington Chemical. BSA, ovalbumin and human immunoglobulin G (IgG) are available from Sigma Chemical of St. Louis, Missouri. G-CSF was obtained from Amgen of Thousand Oaks, California.
EXAMPLE 1 SYNTHESIS OF mPEG-HYDRAZIDE DERIVATIVE CONTAINING BETA-ALANINE: mPEG (MWn 5,000, 100 g, 20 mmol) was dissolved in toluene (250 mL) and azeotropically dried for two hours under reflux. The solution was brought to 25λC, diluted with methylene chloride (50 mL) and then treated with phosgene (30 mL of 20 percent toluene solution, 56 mmol) overnight. The solvents and the excess of phosgene were removed by rotary evaporation under vacuum. The solid residue of polymeric chloroformate was dissolved in methylene chloride (90 mL) and treated with beta-alanine ethyl ester hydrochloride (6.1 g, 40 mmol) predissolved in methylene chloride (total volume 30 mL) followed by triethylamine (8.4 mL, 60 mmol). Approximately 30 minutes later, the solution was diluted with toluene (50 mL) , filtered and
evaporated to dryness. The crude product was dissolved in warm (50XC) ethyl acetate (500 mL) and filtered through celite. The filtrate was diluted with isopropanol to a total volume of 1,000 mL and left overnight at 25XC to facilitate precipitation of the product. Another recrystallization of the product from isopropanol was performed. The yield of dried mPEG-beta-alanine ethyl ester was 98 g (95%) . The following IR and NMR spectrum were then obtained: IR (neat):3341 (N-H) , 1723 (C=0, urethane) CM"1. ^Η-NMR (CDC13) :Delta 1.17 (t, CH3CH20) , 2.44 (t)CH2CH2 of beta-alanine) , 3.64 (PEG), 3.9 (t, NH (C=0) 0CH2) , 4.11(2,CH3CH20) , 5.25 (broad, NH) ppm.
The mPEG-beta-alanine ethyl ester (62 g, 12 mmol) was dissolved in pyridine (120 L) and treated with hydrazine (12 mL, 0.375 mole) under reflux for six hours. The solution was rotary evaporated to dryness and the residue crystallized twice from isopropanol and dried in vacuo over P205. The yield was 60 g (97%) .
The absence of free hydrazine in the product was ascertained by reverse-phase (C-18) thin-layer chromatography in water/methanol (3:1) using TNBS spraying solution for detection. Colorimetric assay of hydrazide groups using
TNBS gave 0.2 mmol/g (103% of theoretical) . The beta-alanine content of the polymer was 0.205 mmol/g (105% of theoretical) as determined by amino acid analysis of a completely hydrolysed (6N HC1, 110 C, 24 h) aliquot of the product. 13C-NMR (CDC13) :delta 171.2 (C=0,hydrazide) ; 156.4 (C=0,urethane) ; 71.8 (CH30CH2) ; 70.0 (PEG); 68.5 (CH2CH20C=0) ; 63.7 (CH2CH20C=0) ; 58.9 (CH30) ; 37.1 (NHCH2CH2) ; 33.9 (NHCH2CH2) ppm. IR (neat):3328 (NH) ; 1719 (C=0,urethane) ; 1671 (C=0,hydrazide) cm-1.
EXAMPLE 2 COUPLING OF mPEG-HYDRAZIDE DERIVATIVE CONTAININ BETA-ALANINE TO EDC-ACTIVATED CARBOXYL GROUPS O CHYMOTRYPSIN: Chymotrypsin (20 mg, 8.0 x 10~7 mole,
1.28 x 10""5 equiv. of carboxyl) and th mPEG-beta-alanine-hydrazide derivative of Example (800 mg, 0.16 mmol) were dissolved in 8 ml of 1 mM HC1, the solution was brought to pH 5.0 and treated with ED (15 mg, 0.078 mmol). The reaction mixture was stirre gently at 25 C overnight while pH 5.0 was maintained b addition of 1.0 N HC1. Excess reagents were removed b extensive diafiltration of the reaction solution at 4 against one mM HC1. In order to determine the extent o the coupling reaction, an aliquot of th PEG-chymotrypsin conjugate was completely hydrolyze (6 N HC1, 110 C, 24 hours) and amino acid analysis was performed. The amount of beta-alanine corresponde to 2.4 molecules of mPEG per molecule of chymotrypsin. EXAMPLE 3
COUPLING OF mPEG-HYDRAZIDE DERIVATIVE CONTAININ BETA-ALANINE TO HONb ACTIVATED CARBOXYL GROUPS OF CHYMOTRYPSIN:
The same conjugation protocol as Example 2 was employed, in the presence of HONb (28.7 mg, 0.16 mmol). The PEG-chymotrypsin obtained had an average 2.7 molecules of mPEG per molecule of protein, based on quantitation of beta-alanine by amino acid analysis. This demonstrates that the conjugation process is only slightly enhanced by the presence of HONb.
EXAMPLE 4 COUPLING OF mPEG-HYDRAZIDE DERIVATIVE CONTAINING BETA-ALANINE TO EDC-ACTIVATED CARBOXYL GROUPS OF BSA: A solution of BSA (20 mg) and a mPEG-beta-alanine hydrazide derivative of Example 1 (800 mg, 0.16 mmol) in 50 mM NaCl (10 mL) was treated with EDC (15 mg, 0.078 mmol) overnight at pH 5.0, 25 C
as in Example 2. Excess reagents were removed by extensive diafiltration of the reaction solution at 4ΛC against phosphate buffer (50 mM, pH 7.7). The content of beta-alanine in the conjugate corresponded to 8.1 residues of mPEG per molecule of BSA. A GF-HPLC comparison of the PEG-conjugate to native BSA was performed with a BIOSEP SEC 4000 column, the results of which are depicted in FIG. 1. The elution conditions were 10% (vol/vol) methanol/40 mM phosphate buffer. FIG. 1 depicts good homogeneity of the PEG-conjugate 1, with a substantially increased molecular weight as compared to the native BSA 2.
EXAMPLE 5 COUPLING OF mPEG-HYDRAZIDE DERIVATIVE CONTAINING BETA- ALANINE TO OXIDIZED CARBOHYDRATE MOIETIES OF OVALBUMIN:
Ovalbumin (20 mg, 4.4 x 10~7 mole) dissolved in Phosphate Buffered Saline (PBS) buffer, pH 6.0 (1.8 mL) was treated with NaI04 (0.2 mL of 200 mM aqueous solution) . The reaction was allowed to proceed in the dark at 4ΛC. After one hour, the oxidized glycoprotein was separated from the excess of periodate by passing the reaction solution through a 12 mL Sephadex G-25 column equilibrated with acetate buffer to pH 5.0. Additional samples were prepared and the procedure was repeated equilibrating the column with PBS buffer at pH 6.0 and phosphate buffer at pH 7.0. This resulted in three separate reaction mixtures having different buffering systems. To each mixture was added the mPEG-beta-alanine-hydrazide derivative of Example 1 (150 mg, 2.9 x 10""5 mole). Each of the three reaction mixtures was divided into two equal portions and NaCNBH3 (0.3 mL of 6.6 mg/mL solution, 3.15 x 10~5 mole) was added to one portion of each. The reactions were allowed to proceed overnight at 4 C. Each solution was diafiltered using phosphate buffer pH 7.7 until all the unreacted reagents were removed. The conjugates in the solutions to which the NaCNBH3 was added formed
* The average number of mPEG chains attached to an ovalbumin molecule was calculated from the results of amino acid analysis of the conjugates.
Depicted in FIG. 2 is the GF-HPLC analysis using a TSK G 4000SW column and a 10% (vol/vol) methanol/40 mM phosphate buffer pH 7.5 mobile phase, which showed good homogeneity of the mPEG-ovalbumin conjugate 3, and a substantially increased molecular weight as compared to the native ovalbumin 4.
EXAMPLE 6 ATTACHMENT OF mPEG-HYDRAZIDE DERIVATIVE CONTAINING BETA- ALANINE TO THE CARBOHYDRATE MOIETY OF IMMUNOGLOBULIN G:
Human immunoglobulin G (IgG)
(5 mg, 3.12 x 10~5 mmol) in PBS (0.8 mL, 50 mM, pH 6.0) was treated with a freshly prepared solution of sodium periodate (0.2 mL, 200 mM) in PBS. The resulting solution was incubated at 4λC. After one hour, the oxidized glycoprotein was separated from the excessive periodate by passing the reaction solution through a 12 mL Sephadex G-25 column. The oxidized IgG was collected and treated with the mPEG-beta-alanine hydrazide derivative of Example 1
(200 mg, 1.25 x 10 ,-3J mmol) at 4 C overnight, Each solution was diafiltered using phosphate buffer pH 7.7
until all unreacted reagents were removed. A GF-HPLC comparison of the conjugate to native IgG was performed with a ZORBAX GF-450 column, the results of which are depicted in FIG. 3. A 0.2 M phosphate buffer, pH 7.5 mobile phase was used. FIG. 3 depicts good homogeneity of the PEG-conjugate 5, with a substantially increased molecular weight as compared to the native IgG 6. The amount of beta-alanine was determined by amino acid analysis of a hydrolyzed (6 N HCl, 110 C, 24 h) aliquot of the PEG-IgG conjugate to correspond to six residues of mPEG per protein molecule.
EXAMPLE 7 ATTACHMENT OF mPEG-HYDRAZIDE DERIVATIVE CONTAINING BETA-ALANINE TO THE CARBOHYDRATE MOIETY OF IMMUNOGLOBULIN G WITHOUT REMOVAL OF EXCESS PERIODATE:
IgG (5.4 mg, 3.37 x 10~5 mmol) and PBS
(50 mM, 0.91 mL) was treated with a freshly prepared solution of sodium periodate (0.09 mL of 110 mM) at 4 C in the dark. After one hour, mPEG-beta-alanine hydrazide (100 g, 6.3 x 10~4 mmol) was added to the reaction mixture, which was then incubated overnight at 4ΛC. The solution was diafiltered against phosphate buffer at pH 7.7 until all the unreacted reagents were removed. Pure PEG-IgG was obtained, which was determined by amino acid analysis of the beta-alanine content of a hydrolyzed aliquot of the conjugate
(6 N HCl, 110λC, 24 h) to contain 8.6 residues of mPEG per molecule of IgG.
In addition to requiring fewer manipulations, it appears that this one-pot conjugation procedure is more efficient than the one described in EXAMPLE 6.
EXAMPLE 8 ATTACHMENT OF mPEG-HYDRAZIDE DERIVATIVE TO CARBODIIMIDE- ACTIVATED CARBOXYL GROUPS OF G-CSF: The mPEG-beta-alanine-hydrazide of Example 1
(15.0 g, 2.9 mmol) was added to a solution of G-CSF (86 mg, 4.78 x 10~6 mole) in 1 mM HCl (86 mL) , followed by EDC (128 mg, 0.667 mmol). The reaction mixture was
gently stirred at 25 C for 90 minutes while maintainin the pH at about 4.7 to 5.0. Excess reagents were removed by extensive diafiltration of the reactio solution at 4XC against l mM HCl. A GF-HPLC compariso of the PEG-conjugate to native G-CSF was performed using a ZORBAX GF-450 column, the results of which are depicted in FIG. 4. The mobile phase was 0.2 M phosphate buffer pH 7.5. FIG. 4 depicts PEG-conjugate 7, with a substantially increased molecular weight as compared to native G-CSF 8.
The average number of mPEG residues in the PEG-G-CSF was 5.8, as determined by measuring the amount of beta-alanine in an hydrolyzed (6 N HCl, 110 C, 24 h) aliquot of the conjugate. TNBS assay confirmed that both native and PEG-modified G-CSF-1 had the same number of amino groups, indicating that the EDC activated carboxylic acid groups of the protein did not react with amino groups of the protein. The preparation of mPEG-G-CSF gave four separate bands on SDS-PAGE (PhastGel-, Homogenous 12.5, Pharmacia) in the range from 29,000 to 67,000 daltons. Isoelectric Focusing (PhastGel-, IEF 3-9, Pharmacia) of the mPEG-G-CSF-1 resulted in the separation of six bands with pi's arranging between 6.8 and 9.0, noticeably higher than the native protein (pi 5.2; 5.9). This clearly indicates that the protein became more basic as a result of the conjugation with the peptide carboxylic acid groups without crosslinking of the activated carboxylic acid groups with the peptide amino groups. As will be readily appreciated, numerous variations and combinations of the features set forth above can be utilized without departing from the present invention as set forth in the claims. Such variations are not regarded as a departure from the spirit and scope of the invention, and all such modifications are intended to be included within the scope of the following claims.
Industrial Applicability
The present invention is applicable to the production of polymers conjugated with various biologically active and pharmaceutically active compounds representing a novel form of drug delivery.
Claims (24)
1. A biologically active macromolecular conjugate comprising a biologically active polypeptide or glycopolypeptide and one or more water-soluble polymers covalently bonded thereto at a reactive carbonyl or carboxylic acid group of a peptide moiety on said polypeptide or glycopolypeptide by a linkage containing a hydrazide or hydrazone functional group.
2. The macromolecular conjugate of claim 1, wherein said biologically active polypeptide or glycopolypeptide comprises a polypeptide.
3. The macromolecular conjugate of claim 2, wherein said polypeptide is an enzyme.
4. The macromolecular conjugate of claim 3, wherein said enzyme is selected from the group consisting of asparaginase, arginase, adenosine deaminase, superoxide dismutase, catalase, chymotrypsin, lipase, uricase, bilirubin oxidase, glucose oxidase, glucosidase, galactosidase, glucocerebrosidase and glucuronidase.
5. The macromolecular conjugate of claim 2, wherein said polypeptide is selected from the group consisting of Factor VIII, insulin, ACTH, glucagon, somatostatin, somatotropins, thymosin, parathyroid hormone, pigmentary hormones, somatomedins, erythropoietin, luteinizing hormone, hypothalmic releasing factors, antidiuretic hormones, prolactin, interleukins, interferons and colony stimulating factors.
6. The macromolecular conjugate of claim 1, wherein said biologically active polypeptide or glycopolypeptide comprises a glycopolypeptide selected from the group consisting of immunoglobulins, ovalbumin, lipase, glycocerebrosidase, lectins, tissue plasminogen activator and glycosilated interleukins, interferons and colony stimulating factors.
7. The macromolecular conjugate of claim 1, wherein said linkage further includes a peptide sequence binding said hydrazide or hydrazone functional group to said polymer.
8. The macromolecular conjugate of claim 1, wherein said reactive carbonyl group is a ketone or aldehyde group generated on said peptide moiety.
9. A biologically active macromolecular conjugate comprising a biologically active glycopolypeptide and one or more water-soluble polymers covalently bonded thereto at an oxidized carbohydrate moiety of said glycopolypeptide by a linkage containing a hydrazide or hydrazone functional group bound to said polymer by a peptide sequence.
10. The macromolecular conjugate of claim 1 or claim 9, wherein said water-soluble polymer is selected from the group consisting of polyalkylene oxides, polyoxyethylenated polyols, polyvinyl alcohol, polyacrylamides, polyvinyl pyrrolidone and dextran.
11. The macromolecular conjugate of claim 10, wherein said polyalkylene oxide is a polyethylene glycol homopolymer.
12. The macromolecular conjugate of claim 11, wherein said polyethylene glycol homopolymer is a methoxylated polyethylene glycol homopolymer.
13. The macromolecular conjugate of claim 10, wherein said polyalkylene oxide is a block copolymer of polyethylene glycol with polypropylene glycol or polypropylene oxide.
14. The macromolecular conjugate of claim 10, wherein said polyoxyethylenated polyols are selected from the group consisting of polyoxyethylenated glycerols, polyoxyethylenated sorbitols and polyoxyethylenated glucoses.
15. The macromolecular conjugate of claim 1 or claim 9, wherein said water-soluble polymer has a number average molecular weight between about 600 and about 100,000 daltons.
16. The macromolecular conjugate of claim 15, wherein said water-soluble polymer has a number average molecular weight between about 2,000 and about 20,000 daltons.
17. The macromolecular conjugate of claim 9, wherein said glycopolypeptide is selected from the group consisting of immunoglobulins, ovalbumin, lipase, glycocerebrosidase lectins, tissue plasminogen activator and glycosilated interleukins, interferons and colony stimulating factors.
18. The macromolecular conjugate of claim 6 or 7, wherein said immunoglobulin is selected from the group consisting of IgG, igE, igM, igA, IgD and fragments thereof.
19. The macromolecular conjugate of claim 7 or 9, wherein said peptide sequence consists essentially of one amino acid.
20. The macromolecular conjugate of claim 7 or 9, wherein said peptide sequence comprises one or more amino acids that do not appear naturally in proteins.
21. The macromolecular conjugate of claim 20, wherein said amino acids are independently selected from the group consisting of alpha-amino butyric acid, gamma-amino butyric acid, norleucine, homoserine, beta-alanine and epsilon-caproic acid.
22. The macromolecular conjugate of claim 7 or 9, wherein said peptide sequence contains up to six amino acids.
23. The macromolecular conjugate of claim 7 or 9, wherein said amino acids occur naturally in proteins.
24. The macromolecular conjugate of claim 7 or 9, wherein said peptide sequence forms a urethane group with said polymer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67269691A | 1991-03-18 | 1991-03-18 | |
US672696 | 1991-03-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AU1676992A true AU1676992A (en) | 1992-10-21 |
Family
ID=24699627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU16769/92A Abandoned AU1676992A (en) | 1991-03-18 | 1992-03-12 | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0576589A4 (en) |
JP (1) | JPH06506217A (en) |
AU (1) | AU1676992A (en) |
CA (1) | CA2101918A1 (en) |
WO (1) | WO1992016555A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU658231B2 (en) * | 1991-10-21 | 1995-04-06 | Ortho Pharmaceutical Corporation | Conjugation of polymer to polypeptide |
Families Citing this family (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5169627A (en) * | 1991-10-28 | 1992-12-08 | Mount Sinai School Of Medicine Of The City University Of New York | Oral pharmaceutical composition containing a polyethylene glycol-immunoglobulin G conjugate for reconstitution of secretory immunity and method of reconstituting secretory immunity |
NO934477L (en) * | 1992-12-09 | 1994-06-10 | Ortho Pharma Corp | PEG hydrazone and PEG oxime-binding reagents and protein derivatives thereof |
NZ250375A (en) * | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
WO1994015625A1 (en) * | 1993-01-15 | 1994-07-21 | Enzon, Inc. | Factor viii - polymeric conjugates |
US5581476A (en) * | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
US5516703A (en) * | 1993-08-20 | 1996-05-14 | The University Of Utah | Coating of hydrophobic surfaces to render them protein resistant while permitting covalent attachment of specific ligands |
WO1994028024A1 (en) * | 1993-06-01 | 1994-12-08 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
WO1995000162A1 (en) * | 1993-06-21 | 1995-01-05 | Enzon, Inc. | Site specific synthesis of conjugated peptides |
US6284503B1 (en) | 1993-08-20 | 2001-09-04 | University Of Utah Research Foundation | Composition and method for regulating the adhesion of cells and biomolecules to hydrophobic surfaces |
DK0730470T3 (en) * | 1993-11-10 | 2002-06-03 | Enzon Inc | Improved interferon polymer conjugates |
US5951974A (en) * | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
US5446090A (en) * | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US5629384A (en) * | 1994-05-17 | 1997-05-13 | Consiglio Nazionale Delle Ricerche | Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces |
US5738846A (en) * | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
SE9503380D0 (en) * | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
AU778790B2 (en) * | 1996-08-02 | 2004-12-23 | Ortho-Mcneil Pharmaceutical, Inc. | Polypeptides having a single covalently bound n-terminal water-soluble polymer |
RU2199347C2 (en) * | 1996-08-02 | 2003-02-27 | Орто-Макнейл Фармасьютикал, Инк. | Polypeptides comprising a single covalently bound n-terminal water-soluble polymer |
WO1998049198A1 (en) | 1997-04-30 | 1998-11-05 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
JP3688111B2 (en) * | 1998-03-13 | 2005-08-24 | 科学技術振興事業団 | Solid phase synthesis of resin-immobilized hydrazide and its derivatives and pyrazolones |
US6333396B1 (en) | 1998-10-20 | 2001-12-25 | Enzon, Inc. | Method for targeted delivery of nucleic acids |
JP2002542304A (en) * | 1999-04-28 | 2002-12-10 | ベクトレイムド インコーポレイテッド | Enzymatically activated polymerized drug conjugate |
JP4524923B2 (en) * | 1999-05-19 | 2010-08-18 | 日油株式会社 | Polymers, biodegradable materials and applications |
EP1757311B1 (en) | 1999-12-24 | 2009-02-11 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
JP2003518075A (en) | 1999-12-24 | 2003-06-03 | ジェネンテック・インコーポレーテッド | Methods and compositions for extending the elimination half-life of bioactive compounds |
ATE435033T1 (en) | 2000-01-10 | 2009-07-15 | Maxygen Holdings Ltd | G-CSF CONJUGATES |
RU2278123C2 (en) | 2000-02-11 | 2006-06-20 | Максиджен Холдингз Лтд. | Molecules similar to factor vii or viia |
US20030211094A1 (en) | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
BR0207576A (en) | 2001-02-27 | 2004-04-27 | Maxygen Aps | Glycosylated variant of an interferon beta precursor (ifnb) polypeptide, processes for increasing the in vivo glycosylation of a precursor ifnb molecule, producing a glycosylated ifnb molecule, preparing a conjugated variant, and treating a mammal with multiple sclerosis pharmaceutical composition , variant ifnb molecule, nucleotide sequence, expression vector, conjugated glycosylation host cell, and use of a conjugate |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
JP2005525302A (en) * | 2001-11-20 | 2005-08-25 | ファルマシア・コーポレーション | Chemically modified human growth hormone conjugates |
UA86744C2 (en) | 2002-06-21 | 2009-05-25 | Ново Нордиск Хэлс Кеа Аг | Pegylated factor vii glycoforms |
US7459435B2 (en) | 2002-08-29 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
US7459436B2 (en) | 2002-11-22 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
AU2003303635B2 (en) | 2002-12-26 | 2009-07-23 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of interferon-beta with enhanced biological potency |
WO2004061094A1 (en) | 2002-12-30 | 2004-07-22 | Gryphon Therapeutics, Inc. | Water-soluble thioester and selenoester compounds and methods for making and using the same |
CN1767857A (en) | 2003-02-26 | 2006-05-03 | 尼克塔治疗亚拉巴马公司 | Polymer-factor VIII moiety conjugates |
BRPI0408946A (en) * | 2003-03-28 | 2006-04-04 | Biopolymed Inc | biocompatible polymer conjugated biologically active material with 1: 1 complex, its preparation process and pharmaceutical composition comprising the same |
EP2338333B1 (en) | 2003-04-09 | 2017-09-06 | ratiopharm GmbH | Glycopegylation methods and proteins/peptides produced by the methods |
EP2261244A3 (en) | 2003-04-15 | 2011-02-23 | Glaxosmithkline LLC | Human il-18 substitution mutants and their conjugates |
PT1625156E (en) | 2003-05-12 | 2013-01-09 | Affymax Inc | Peptides that bind to the erythropoietin receptor |
KR101163683B1 (en) | 2003-05-12 | 2012-07-10 | 아피맥스, 인크. | Novel peptides that bind to the erythropoietin receptor |
CN1849141A (en) * | 2003-05-12 | 2006-10-18 | 阿费麦克斯公司 | Spacer moiety for poly(ethylene glycol)-modified peptide- based compounds |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
WO2005014035A2 (en) * | 2003-08-08 | 2005-02-17 | Novo Nordisk Health Care Ag | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest |
DE602004029173D1 (en) | 2003-10-10 | 2010-10-28 | Novo Nordisk As | IL-21 DERIVATIVES |
EP2641611A3 (en) | 2003-10-17 | 2013-12-18 | Novo Nordisk A/S | Combination therapy |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
ES2460671T3 (en) | 2003-12-19 | 2014-05-14 | F. Hoffmann-La Roche Ag | Use of erythropoietin in the treatment of iron distribution disorders in chronic inflammatory bowel diseases |
JP2007519422A (en) | 2004-02-02 | 2007-07-19 | アンブレツクス・インコーポレイテツド | Modified human four helix bundle polypeptides and their use |
WO2005123140A2 (en) | 2004-06-08 | 2005-12-29 | Alza Corporation | Preparation of macromolecular conjugates by four-component condensation reaction |
MXPA06014684A (en) | 2004-06-18 | 2007-02-12 | Ambrx Inc | Novel antigen-binding polypeptides and their uses. |
EP1765412A2 (en) | 2004-07-08 | 2007-03-28 | Elan Pharmaceuticals, Inc. | Multivalent vla-4 antagonists comprising polyethylene glycol moieties |
SI2586456T1 (en) | 2004-10-29 | 2016-05-31 | Ratiopharm Gmbh | Remodeling and glycopegylation of fibroblast growth factor (FGF) |
BRPI0519430A2 (en) | 2004-12-22 | 2009-02-10 | Ambrx Inc | modified human growth hormone |
ATE541934T1 (en) | 2004-12-22 | 2012-02-15 | Ambrx Inc | AMINOACYL TRNA SYNTHETASE COMPOSITIONS AND USES THEREOF |
AU2005322019B2 (en) | 2004-12-22 | 2010-08-26 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid |
SG161210A1 (en) | 2004-12-22 | 2010-05-27 | Ambrx Inc | Methods for expression and purification of recombinant human growth hormone |
EP1858543B1 (en) | 2005-01-10 | 2013-11-27 | BioGeneriX AG | Glycopegylated granulocyte colony stimulating factor |
US20100092505A1 (en) | 2005-04-05 | 2010-04-15 | Elisabetta Bianchi | Method for Shielding Functional Sites or Epitopes on Proteins |
US7341720B2 (en) | 2005-04-06 | 2008-03-11 | Genzyme Corporation | Targeting of glycoprotein therapeutics |
WO2006121569A2 (en) | 2005-04-08 | 2006-11-16 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
KR20080026135A (en) | 2005-06-03 | 2008-03-24 | 암브룩스, 인코포레이티드 | Improved human interferon molecules and their uses |
US7550433B2 (en) | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
US8324159B2 (en) | 2005-06-03 | 2012-12-04 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
EP2360170A3 (en) | 2005-06-17 | 2012-03-28 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered proteins comprinsing at least one non-native cysteine |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
EP2339014B1 (en) | 2005-11-16 | 2015-05-27 | Ambrx, Inc. | Methods and compositions comprising non-natural amino acids |
US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
US7985839B2 (en) | 2006-03-31 | 2011-07-26 | Baxter International Inc. | Factor VIII polymer conjugates |
US7982010B2 (en) | 2006-03-31 | 2011-07-19 | Baxter International Inc. | Factor VIII polymer conjugates |
CA2647314A1 (en) | 2006-03-31 | 2007-11-08 | Baxter International Inc. | Pegylated factor viii |
US20090252720A1 (en) | 2006-05-24 | 2009-10-08 | Novo Nordisk Health Care Ag | Prolonged FIX Analogues and Derivatives |
CN101516388B (en) | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | Glycosylation of peptides via O-linked glycosylation sequences |
WO2008025856A2 (en) | 2006-09-01 | 2008-03-06 | Novo Nordisk Health Care Ag | Modified glycoproteins |
US8420792B2 (en) | 2006-09-08 | 2013-04-16 | Ambrx, Inc. | Suppressor tRNA transcription in vertebrate cells |
EP2069396B1 (en) | 2006-09-08 | 2015-10-21 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and their uses |
NZ574721A (en) | 2006-09-08 | 2012-02-24 | Ambrx Inc | Hybrid suppressor trna for vertebrate cells |
US7985783B2 (en) | 2006-09-21 | 2011-07-26 | The Regents Of The University Of California | Aldehyde tags, uses thereof in site-specific protein modification |
EP2054521A4 (en) | 2006-10-03 | 2012-12-19 | Novo Nordisk As | Methods for the purification of polypeptide conjugates |
DK2101821T3 (en) | 2006-12-15 | 2014-10-06 | Baxter Healthcare Sa | Factor VIIA (poly) sialic acid conjugate with extended half-life in vivo |
CN102978185B (en) | 2007-01-18 | 2015-02-11 | 建新公司 | Oligosaccharides comprising an aminooxy group and conjugates thereof |
JP2010520855A (en) | 2007-01-31 | 2010-06-17 | アフィーマックス・インコーポレイテッド | Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules |
BRPI0809583B1 (en) | 2007-03-30 | 2022-02-22 | Ambrx, Inc | Modified fgf-21 polypeptide, composition comprising the same, method for producing said fgf-21 polypeptide, and cell comprising a polynucleotide |
ES2406267T3 (en) | 2007-04-03 | 2013-06-06 | Biogenerix Ag | Treatment methods using glycopegylated G-CSF |
CA2685596A1 (en) | 2007-05-02 | 2008-11-13 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
WO2008154639A2 (en) | 2007-06-12 | 2008-12-18 | Neose Technologies, Inc. | Improved process for the production of nucleotide sugars |
NZ603812A (en) | 2007-11-20 | 2014-06-27 | Ambrx Inc | Modified insulin polypeptides and their uses |
SG188143A1 (en) | 2008-02-08 | 2013-03-28 | Ambrx Inc | Modified leptin polypeptides and their uses |
PL2257311T3 (en) | 2008-02-27 | 2014-09-30 | Novo Nordisk As | Conjugated factor viii molecules |
NZ591235A (en) | 2008-07-23 | 2012-07-27 | Ambrx Inc | Modified bovine g-csf polypeptides comprising non natural amino acid and their uses treating infections such as mastitis |
PL2342223T3 (en) | 2008-09-26 | 2017-09-29 | Ambrx, Inc. | Modified animal erythropoietin polypeptides and their uses |
TR201802361T4 (en) | 2008-09-26 | 2018-03-21 | Ambrx Inc | Microorganisms and vaccines dependent on unnatural amino acid replication. |
ITRM20080551A1 (en) * | 2008-10-15 | 2010-04-16 | Univ Catania | AMPHIFYL DERIVATIVES OF POLYOSSIETHYLENE GLYCOL (PEG), PREPARATION PROCEDURE AND THEIR USE IN THE PREPARATION OF PHARMACEUTICAL SYSTEMS. |
KR20100052730A (en) * | 2008-11-11 | 2010-05-20 | 한국유니온제약 주식회사 | A novel conjugate of erythropoietin and biocompatible polymer |
SI2889043T1 (en) | 2008-12-16 | 2019-08-30 | Genzyme Corporation | Synthetic intermediates for preparing oligosaccharide-protein conjugates |
US20110318322A1 (en) * | 2009-01-12 | 2011-12-29 | Nektar Therapeutics | Conjugates of a Lysosomal Enzyme Moiety and a Water Soluble Polymer |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
HUE028056T2 (en) | 2009-07-27 | 2016-11-28 | Baxalta GmbH | Blood coagulation protein conjugates |
JP5908401B2 (en) | 2009-07-27 | 2016-04-26 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | Blood coagulation protein complex |
WO2011012850A2 (en) * | 2009-07-27 | 2011-02-03 | Lipoxen Technologies Limited | Glycopolysialylation of non-blood coagulation proteins |
US8945575B2 (en) * | 2009-12-01 | 2015-02-03 | Trustees Of Boston University | Treatment of IgE-mediated disease |
NZ600361A (en) | 2009-12-21 | 2014-06-27 | Ambrx Inc | Modified bovine somatotropin polypeptides and their uses |
CN104017063A (en) | 2009-12-21 | 2014-09-03 | Ambrx公司 | Modified porcine somatotropin polypeptides and their uses |
JP6148013B2 (en) | 2010-03-05 | 2017-06-14 | リグショスピタレト | Chimera inhibitor molecule of complement activation |
EP2569331A1 (en) | 2010-05-10 | 2013-03-20 | Perseid Therapeutics LLC | Polypeptide inhibitors of vla4 |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
MY162837A (en) | 2010-08-17 | 2017-07-31 | Ambrx Inc | Modified relaxin polypeptides and their uses |
AR083006A1 (en) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | FORMULATIONS FOR THE STIMULATING FACTOR OF COLONIES OF GRANULOCITS (G-CSF) BOVINE AND VARIANTS OF THE SAME |
CA2822591C (en) | 2010-12-22 | 2020-12-29 | Baxter International Inc. | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
CN103930440A (en) | 2011-07-01 | 2014-07-16 | 拜耳知识产权有限责任公司 | Relaxin fusion polypeptides and uses thereof |
CN103747807B (en) | 2011-07-05 | 2016-12-07 | 比奥阿赛斯技术有限公司 | P97 antibody conjugates and using method |
WO2013138731A1 (en) * | 2012-03-16 | 2013-09-19 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates of c1-inhibitors |
EP2859017B1 (en) | 2012-06-08 | 2019-02-20 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
DK2863955T3 (en) | 2012-06-26 | 2017-01-23 | Sutro Biopharma Inc | MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF |
EP2880156B1 (en) | 2012-07-31 | 2017-08-23 | biOasis Technologies Inc | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
EP3584255B1 (en) | 2012-08-31 | 2022-02-16 | Sutro Biopharma, Inc. | Modified amino acids comprising an azido group |
CA2890190A1 (en) | 2012-11-12 | 2014-05-15 | Redwood Bioscience, Inc. | Compounds and methods for producing a conjugate |
US9310374B2 (en) | 2012-11-16 | 2016-04-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
JP2016505528A (en) | 2012-11-16 | 2016-02-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Picte-Spengler ligation for chemical modification of proteins |
WO2014160438A1 (en) | 2013-03-13 | 2014-10-02 | Bioasis Technologies Inc. | Fragments of p97 and uses thereof |
EA023323B1 (en) * | 2013-03-28 | 2016-05-31 | Илья Александрович МАРКОВ | Branched acyl azide pegylating agent, method for preparing the same and method for preparing pegylated interferon |
EA022617B1 (en) * | 2013-03-28 | 2016-02-29 | Илья Александрович МАРКОВ | Monopegylated interferon-alpha of branched structure and a pharmaceutical composition for preparing a medicament having interferon-alpha activity |
EA021610B1 (en) * | 2013-03-28 | 2015-07-30 | Илья Александрович МАРКОВ | Liquid antiviral formulation |
EA023360B1 (en) * | 2013-03-28 | 2016-05-31 | Илья Александрович МАРКОВ | Linear acyl azide pegylating agent, method for preparing the same anf method for preparing pegylated interferon |
EA021643B1 (en) * | 2013-03-28 | 2015-07-30 | Илья Александрович МАРКОВ | Monopegylated interferon-alpha of linear structure and a pharmaceutical composition for preparing a medicament having interferon-alpha activity |
US9764039B2 (en) | 2013-07-10 | 2017-09-19 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
EP3038657A2 (en) | 2013-08-28 | 2016-07-06 | Bioasis Technologies Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
US9840493B2 (en) | 2013-10-11 | 2017-12-12 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
JP6745218B2 (en) | 2013-11-27 | 2020-08-26 | レッドウッド バイオサイエンス, インコーポレイテッド | Methods for producing hydrazinyl-pyrrolo compounds and conjugates |
UY36370A (en) | 2014-10-24 | 2016-04-29 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | MODIFIED FGF-21 POLIPEPTIDES AND ITS USES |
AU2016277147A1 (en) * | 2015-06-11 | 2018-01-18 | Ambio Pharmaceuticals, Llc | Pegylated granulocyte colony stimulating factor (GCSF) |
ES2826827T3 (en) | 2015-06-15 | 2021-05-19 | Angiochem Inc | Methods for the treatment of leptomeningeal carcinomatosis |
ES2963839T3 (en) | 2017-02-08 | 2024-04-02 | Bristol Myers Squibb Co | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
US11529424B2 (en) | 2017-07-07 | 2022-12-20 | Symic Holdings, Inc. | Synthetic bioconjugates |
US11492493B2 (en) | 2017-12-26 | 2022-11-08 | Becton, Dickinson And Company | Deep ultraviolet-excitable water-solvated polymeric dyes |
JP2021519841A (en) | 2018-03-30 | 2021-08-12 | ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company | Water-soluble polymer dye with pendant chromophore |
CA3107332A1 (en) | 2018-07-22 | 2020-01-30 | Bioasis Technologies Inc. | Treatment of lymphatic metastases |
HRP20240016T1 (en) | 2018-09-11 | 2024-03-29 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and their uses |
CN113366015A (en) | 2018-10-19 | 2021-09-07 | Ambrx公司 | Interleukin-10 polypeptide conjugates, dimers thereof and uses thereof |
BR112021015832A2 (en) | 2019-02-12 | 2022-01-18 | Ambrx Inc | Compositions containing antibody-tlr agonist conjugates, methods and uses thereof |
WO2021183832A1 (en) | 2020-03-11 | 2021-09-16 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
US20210355468A1 (en) | 2020-05-18 | 2021-11-18 | Bioasis Technologies, Inc. | Compositions and methods for treating lewy body dementia |
US20210393787A1 (en) | 2020-06-17 | 2021-12-23 | Bioasis Technologies, Inc. | Compositions and methods for treating frontotemporal dementia |
AU2021327396A1 (en) | 2020-08-20 | 2023-03-23 | Ambrx, Inc. | Antibody-TLR agonist conjugates, methods and uses thereof |
AU2022249223A1 (en) | 2021-04-03 | 2023-10-12 | Ambrx, Inc. | Anti-her2 antibody-drug conjugates and uses thereof |
EP4155349A1 (en) | 2021-09-24 | 2023-03-29 | Becton, Dickinson and Company | Water-soluble yellow green absorbing dyes |
WO2024007016A2 (en) | 2022-07-01 | 2024-01-04 | Beckman Coulter, Inc. | Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives |
WO2024044327A1 (en) | 2022-08-26 | 2024-02-29 | Beckman Coulter, Inc. | Dhnt monomers and polymer dyes with modified photophysical properties |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL45247A0 (en) * | 1974-07-11 | 1974-10-22 | Yeda Res & Dev | Water insoluble protein preparations |
JPS5399384A (en) * | 1977-02-04 | 1978-08-30 | Toyo Tire & Rubber Co Ltd | Novel process for immobilization of enzyme |
US4684728A (en) * | 1979-01-12 | 1987-08-04 | Bayer Aktiengesellschaft | Solubilizing biologically active compounds with reactive hydrogen atoms |
US4970300A (en) * | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4847325A (en) * | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
ATE300519T1 (en) * | 1989-04-19 | 2005-08-15 | Enzon Inc | METHOD FOR PRODUCING MODIFIED POLYPEPTIDES CONTAINING A POLYPEPTIDE AND A POLYALKYLENE OXIDE |
DD287950A5 (en) * | 1989-09-15 | 1991-03-14 | Adw Zi F. Molekularbiologie,De | PROCESS FOR THE COVALENT BINDING OF BIOLOGICALLY ACTIVE COMPOUNDS TO SUBSTITUTED POLYOXYALKYLENE GLYCOLS AND THEIR MONOALKOXY DERIVATIVES |
-
1992
- 1992-03-12 WO PCT/US1992/002047 patent/WO1992016555A1/en not_active Application Discontinuation
- 1992-03-12 JP JP4508914A patent/JPH06506217A/en active Pending
- 1992-03-12 CA CA002101918A patent/CA2101918A1/en not_active Abandoned
- 1992-03-12 AU AU16769/92A patent/AU1676992A/en not_active Abandoned
- 1992-03-12 EP EP19920909326 patent/EP0576589A4/en not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU658231B2 (en) * | 1991-10-21 | 1995-04-06 | Ortho Pharmaceutical Corporation | Conjugation of polymer to polypeptide |
Also Published As
Publication number | Publication date |
---|---|
JPH06506217A (en) | 1994-07-14 |
EP0576589A4 (en) | 1994-07-27 |
EP0576589A1 (en) | 1994-01-05 |
CA2101918A1 (en) | 1992-09-19 |
WO1992016555A1 (en) | 1992-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU1676992A (en) | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers | |
US5643575A (en) | Non-antigenic branched polymer conjugates | |
US7511095B2 (en) | Thioester-terminated water soluble polymers and method of modifying the N-terminus of a polypeptide therewith | |
US6566506B2 (en) | Non-antigenic branched polymer conjugates | |
US5321095A (en) | Azlactone activated polyalkylene oxides | |
US7419600B2 (en) | Method for purifying a branched water-soluble polymer | |
WO1994028024A1 (en) | Carbohydrate-modified polymer conjugates with erythropoietic activity | |
WO1996041813A2 (en) | Functionalized polymers for site-specific attachment | |
JP2006321808A (en) | Chemically modified human growth hormone conjugate | |
AU2002360257A1 (en) | Thioester-terminated water soluble polymers and method of modifying the N-terminus of a polypeptide therewith | |
NZ244778A (en) | Peg imidates and protein derivatives thereof | |
US20070117924A1 (en) | Biologically active material conjugated with biocompatible polymer with 1:1 complex, preparation method thereof and pharmaceutical composition comprising the same | |
González et al. | Evolution of reactive mPEG polymers for the conjugation of peptides and proteins | |
Bonora et al. | Reactive PEGs for protein conjugation |